I\'m hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much

I'm hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF-1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much

I'm hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF-1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much as they have been.

More From BioPortfolio on "I'm hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF-1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much "